Moderna Inc (MRNA)

147.66
+11.86(+8.73%)
After Hours
146.90
-0.76(-0.51%)
- Real-time Data
  • Volume:
    7,531,727
  • Day's Range:
    136.59 - 148.54
  • 52 wk Range:
    119.01 - 496.71

MRNA Comments

What is your sentiment on Moderna?
or
Market is currently closed. Voting is open during market hours.

All Comments

(10236)
  • The fact that kids are having liver issues can be very bad for these vaccine companies, still don’t know all the side effects of this vaccine
    0
    • I can see this below $100 on Earnings
      0
      • I see a very bad earnings coming out
        0
        • Buy now!
          3
          • 'We are proud to share that we have initiated our EUA submission for authorization for our COVID-19 vaccine for young children," said Stéphane Bancel, Chief Executive Officer of Moderna. "We believe mRNA-1273 will be able to safely protect these children against SARS-CoV-2, which is so important in our continued fight against COVID-19 and will be especially welcomed by parents and caregivers.'
            4
            • 🚀 Great entry point for Therapeutics ready to release from the huge pipeline!
              5
              • This company is getting desperate. Vaccinating infants now ? Seriously ? They just want the government money
                3
                • covid globe it is best isn't it?
                  1
                  • Moderna today announced that Arpa Garay will join Moderna as Chief Commercial Officer, effective Monday, May 31, 2022. She will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel. Ms. Garay joins Moderna from Merck & Co., Inc. (MRK) where she most recently served as Chief Marketing Officer for Merck's Human Health business; she reported to Merck's Chief Executive Officer and was a member of Merck's Executive Committee. In this role, she was responsible for long-term portfolio strategy and global marketing for Merck's in-line and pipeline human health medicines and vaccines, including global market access and pricing strategy, data and analytics, digital marketing, and commercial business development.
                    6
                    • Cool, waiting for new vaccine.
                      4
                      • New variants will keep Moderna consistently developing, keeping the public guarded, and deriving steady revenue upsurges...
                        6
                        • Expect 65$ by end of summer
                          4
                          • Buy now first shares…
                            5
                            • earning forecast is not terrible. they have many trials going on now.
                              2
                              • Im buying first shares at around 145…
                                4
                                • I hear you for the long-term, but I'd buy a protective put for 5.6 in case they say something that freaks everyone out on their earnings call.
                                  0
                              • should be up now
                                2
                                • I believe!
                                  1
                              • earnings forecast is terrible!!
                                3
                                • Ready ri buy strong!
                                  1
                                  • CAMBRIDGE, MA / April 19, 2022 / NASDAQ:MRNA today announced new clinical data on its bivalent COVID-19 booster platform including data on the Company's first bivalent booster candidate, mRNA-1273.211, which includes mutations found in the Beta variant of concern, several of which have been persistent in more recent variants of concern including Omicron. A50 µg booster dose ofmRNA-1273.211 demonstrated superiority against Beta, Delta and Omicron variants of concern one month after administration. Superiority continued six months after administration for Beta and Omicron variants of concern as well. A50 µg booster dose of mRNA-1273.211 was generally well tolerated with a reactogenicity profile comparable to a booster dose of mRNA-1273 at the 50 µg dose level.
                                    2
                                    • tale the vaccine and perish.
                                      2
                                  • Bellow 100$ in summer
                                    4
                                    • Buy dip before Revenue Report in early May!
                                      2
                                      • 💲Moderna announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 4, 2022 to report its first quarter 2022 financial results, and provide a corporate update.
                                        2
                                        • yes, important, good news the sooner the better
                                          1
                                      • And we will buy again and again the compaly that save milions of people! Target price for 2022, 285usd! The murderers are the “people” of the dark ages!
                                        3
                                        • not over bought at this price
                                          1
                                          • health alert in china
                                            1
                                            • The U.S. Department of State authorized the voluntary departure of non-emergency U.S. Government employees and their family members at U.S. Consulate General Shanghai, effective immediately.  The Department of State made this decision due to the surge in COVID-19 cases and impact of restrictions related to the implementation of public health response measures.  While the Consulate General remains closed to the public due to local COVID-19 control measures, it will remain staffed and continue to provide emergency services to U.S. citizens in need.
                                              1